Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | 1.50% | |
Lower Bollinger Band Walk | Weakness | 1.50% | |
Inside Day | Range Contraction | 1.50% | |
Below Lower BB | Weakness | 1.50% | |
Lower Bollinger Band Touch | Weakness | 1.50% | |
Oversold Stochastic | Weakness | 1.50% | |
Lower Bollinger Band Walk | Weakness | 1.16% | |
Below Lower BB | Weakness | 1.16% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 13 hours ago |
Rose Above Lower Bollinger Band | about 13 hours ago |
Up 3% | about 13 hours ago |
Up 2% | about 13 hours ago |
Up 1% | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/29/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.17 |
52 Week Low | 2.0902 |
Average Volume | 196,554 |
200-Day Moving Average | 4.47 |
50-Day Moving Average | 7.02 |
20-Day Moving Average | 6.95 |
10-Day Moving Average | 6.56 |
Average True Range | 0.45 |
RSI (14) | 35.48 |
ADX | 25.62 |
+DI | 17.28 |
-DI | 26.04 |
Chandelier Exit (Long, 3 ATRs) | 6.61 |
Chandelier Exit (Short, 3 ATRs) | 7.20 |
Upper Bollinger Bands | 7.98 |
Lower Bollinger Band | 5.93 |
Percent B (%b) | 0.08 |
BandWidth | 29.37 |
MACD Line | -0.23 |
MACD Signal Line | -0.08 |
MACD Histogram | -0.1515 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.45 | ||||
Resistance 3 (R3) | 6.45 | 6.34 | 6.39 | ||
Resistance 2 (R2) | 6.34 | 6.25 | 6.34 | 6.37 | |
Resistance 1 (R1) | 6.22 | 6.19 | 6.28 | 6.22 | 6.35 |
Pivot Point | 6.11 | 6.11 | 6.14 | 6.10 | 6.11 |
Support 1 (S1) | 5.99 | 6.02 | 6.05 | 5.98 | 5.85 |
Support 2 (S2) | 5.88 | 5.96 | 5.87 | 5.83 | |
Support 3 (S3) | 5.76 | 5.88 | 5.81 | ||
Support 4 (S4) | 5.75 |